Bio-Path Presented Interim Results From Phase 2 Study Of Prexigebersen (BP1001) In Combination With Decitabine And Venetoclax For Acute Myeloid Leukemia At The American Society Of Clinical Oncology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Bio-Path presented interim results from its Phase 2 study of Prexigebersen (BP1001) in combination with Decitabine and Venetoclax for Acute Myeloid Leukemia at the American Society of Clinical Oncology Annual Meeting.
June 03, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path presented promising interim results from its Phase 2 study of Prexigebersen (BP1001) in combination with Decitabine and Venetoclax for Acute Myeloid Leukemia at the ASCO Annual Meeting. This could positively impact the stock price in the short term.
The presentation of promising interim results from a Phase 2 study at a major conference like ASCO is likely to generate positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100